JCT  Vol.4 No.2 A , February 2013
Hepatitis B Virus Genotype H and Environmental Factors Associated to the Low Prevalence of Hepatocellular Carcinoma in Mexico
ABSTRACT

Purpose: Hepatocellular carcinoma (HCC) is a leading health problem worldwide. Any agent causing chronic liver damage and cirrhosis is a risk factor for HCC. Genetic and environmental factors may be responsible for regional variations in the occurrence of HCC worldwide. The aim of this review was to describe the risk factors that may be contributing to low prevalence of HCC in the Mexican population. Methods: An electronic systematic search was conducted in four databases to retrieve studies on hepatocellular carcinoma inMexico. Results: Eighteen publications gave a total of 1042 HCC cases with a percentage that ranged from 0.25% to 1.87%. Cirrhosis was registered in 7 studies while the main etiologies were: HCV (66%), HBV (11%) and alcoholism (6.6%). Conclusions: In the last 50 years, the studies performed inMexicohave shown a very low incidence and/or mortality rate of HCC. These findings contrast from those reported in high endemic regions, such asAsia, where viral hepatitis and HCC are prevalent. One significant difference is the predominance of HBV genotype H in Mexico and HBV/B and C in Asia. InMexico, high endemic areas of HBV infection have been detected, mainly among the native population; however, infection seems to resolve very quickly, due to a prominent immunological response among the population. Other factors are that patients with liver cirrhosis die prematurely before that HCC can be detected. Furthermore, an environmental factor that may exert a protective effect against HCC, in spite of the high consumption of potentially aflatoxin-contaminated food products, is the neutralization of these substances by alkaline treatment. This study shows that genetic and environmental factors associated to HCC among the Mexican population are different from others reported worldwide.


Cite this paper
S. Roman, N. Fierro, L. Moreno-Luna and A. Panduro, "Hepatitis B Virus Genotype H and Environmental Factors Associated to the Low Prevalence of Hepatocellular Carcinoma in Mexico," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 367-376. doi: 10.4236/jct.2013.42A044.
References
[1]   M. C. Kew, “Epidemiology of Chronic Hepatitis B Virus Infection, Hepatocellular Carcinoma, and Hepatitis B Virus-Induced Hepatocellular Carcinoma,” Pathologie Biologie, Vol. 58, No. 4, 2010, pp. 273-277. doi:10.1016/j.patbio.2010.01.005

[2]   S. Franceschi and S. A. Raza, “Epidemiology and Prevention of Hepatocellular Carcinoma,” Cancer Letters, Vol. 286, No. 1, 2009, pp. 5-8. doi:10.1016/j.canlet.2008.10.046

[3]   P. P. Michielsen, S. M. Francque and J. L. van Dongen, “Viral Hepatitis and Hepatocellular Carcinoma,” World Journal of Surgical Oncology, Vol. 3, 2005, p. 27. doi:10.1186/1477-7819-3-27

[4]   S. A. Raza, G. M. Clifford and S. Franceschi, “Worldwide Variation in the Relative Importance of Hepatitis B and Hepatitis C Viruses in Hepatocellular Carcinoma: A Systematic Review,” British Journal of Cancer, Vol. 96, No. 7, 2007, pp. 1127-1134. doi:10.1038/sj.bjc.6603649

[5]   C. Bosetti, B. Cosetta, E, Negri, M. Colombo and C. La Vecchia, “Estimates of the Incidence and Prevalence of Hepatocellular Carcinoma in Italy in 2002 and Projections for the Years 2007 and 2012,” Tumori, Vol. 95, No. 1, 2009, pp. 23-27.

[6]   C. Neuveut, Y. Wie and M. A. Buendia. “Mechanisms of HBV-Related Hepatocarcinogenesis,” Journal of Hepatology, Vol. 52, No. 4, 2010, pp. 594-604. doi:10.1016/j.jhep.2009.10.033

[7]   J. F. Perz, G. L. Armstrong, L. A. Farrinton Y. J. F. Hutin and B. P. Bell, “The Contributions of Hepatitis B Virus and Hepatitis C Virus Infections to Cirrhosis and Primary Liver Cancer Worldwide,” Journal of Hepatology, Vol. 45, No. 4, 2006, pp. 529-538. doi:10.1016/j.jhep.2006.05.013

[8]   J. Bruix, “Clinical Management of Hepatocellular Carcinoma,” Journal of Hepatology, Vol. 35, No. 3, 2001, pp. 421-430. doi:10.1016/S0168-8278(01)00130-1

[9]   G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato, “Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors,” Gastroenterology, Vol. 127, No. 5, 2004, pp. S35-S50. doi:10.1053/j.gastro.2004.09.014

[10]   M. C. Yu and J. M. Yuan, “Environmental Factors and Risk for Hepatocellular Carcinoma,” Gastroenterology, Vol. 127, No. 5, 2004, pp. S72-S78. doi:10.1016/j.gastro.2004.09.018

[11]   C. P. Wild and P. C. Turner, “The Toxicology of Aflatoxins as a Basis for Public Health Decisions,” Mutagenesis, Vol. 17, No. 6, 2002, pp. 471-481. doi:10.1093/mutage/17.6.471

[12]   H. B. El-Serag, M. Lau, K. Eschbach, J. Davila and J. Goodwin, “Epidemiology of Hepatocellular Carcinoma in Hispanics in the United States,” Archives of Internal Medicine, Vol. 167, No. 18, 2007, pp. 1983-1993. doi:10.1001/archinte.167.18.1983

[13]   S. Roman, A. Panduro, Y. Aguilar-Gutierrez, M. Maldonado, M. Vazquez Van-Dyck, E. Martinez-Lopez, et al., “A Low Steady HBsAg Seroprevalence Is Associated with a Low Incidence of HBV-Related Liver Cirrhosis and Hepatocellular Carcinoma in Mexico: A Systematic Review,” Hepatology International, Vol. 3, No. 2, 2009, pp. 343-355. doi:10.1007/s12072-008-9115-9

[14]   S. Roman, Y. Tanaka, A. Khan, F. Kurbanov, H. Kato, M. Mizokami, et al., “Occult hepatitis B in the Genotype H-Infected Nahuas and Huichol Native Mexican Population,” Journal of Medical Virology, Vol. 82, No. 9, 2010, pp. 1527-1536. doi:10.1002/jmv.21846

[15]   A. Panduro, S. Roman, A. Khan, Y. Tanaka, F. Kurbanov, E. Martinez-Lopez, et al., “Molecular Epidemiology of Hepatitis C Virus Genotypes in West Mexico,” Virus Research, Vol. 151, No. 1, 2010, pp. 19-25. doi:10.1016/j.virusres.2010.03.009

[16]   A. I. Burguete-García, C. J. Conde-González, R. Jiménez-Méndez, Y. Juárez-Díaz, E. Meda-Monzón, K. Torres-Poveda, et al., “Hepatitis C Seroprevalence and Correlation between Viral Load and Viral Genotype among Primary Care Clients in Mexico,” Salud Pública de México, Vol. 53, Suppl. 1, 2011, pp. S7-S12. doi:10.1590/S0036-36342011000700003

[17]   “Anuario Estadístico de Morbilidad, 1984-2008,” Secretaria de Salud de México (National Health Secretariat). http://www.dgepi.salud.gob.mx/anuario/html/anuarios.html

[18]   S. García and N. Heredia, “Mycotoxins in Mexico: Epidemiology, Management and Control Strategies,” Mycopatologica, Vol. 162, No. 3, 2006, pp. 255-264. doi:10.1007/s11046-006-0058-1

[19]   D. Guzmán-de-Pena and J. J. Pena-Cabriales, “Regulatory considerations of Aflatoxin Contamination of Food in Mexico,” Revista Latinoamericana de Microbiologia, Vol. 47, No. 3-4, 2005, pp. 160-164.

[20]   C. Vivas-Arceo, B. E. Bastidas-Ramirez and A. Panduro, “Hepatocellular Carcinoma Is Rarely Present in Western Mexico,” Hepatology Research, Vol. 16, No. 1, 1999, pp. 26-35. doi:10.1016/S1386-6346(99)00035-2

[21]   E. Lopez-Corella, C. Ridaura-Sanz and J. Albores-Saavedra, “Primary Carcinoma of the Liver in Mexican Adults,” Cancer, Vol. 22, No. 3, 1968, pp. 678-685. doi:10.1002/1097-0142(196809)22:3<678::AID-CNCR2820220326>3.0.CO;2-U

[22]   T. Cortés-Espinosa, R. Mondragón-Sánchez H. Hurtado Andrade and R. Sánchez-Cisneros, “Hepatocellular Carcinoma and Hepatic Cirrhosis in Mexico: A 25 Year Necroscopy Review,” Hepatogastroenterology, Vol. 44, No. 17, 1997, pp. 1401-1403.

[23]   D. Garcia Compeán, F. J. Guzman de la Garza, L. E. M. Espinoza, R. V. Castillo, A. M. M. Flores, B. A. Fernández, et al., “Primary Liver Cancer. Its Epidemiological, Clinical and Biochemical Characteristics,” Revista de Gastroenterología de México, Vol. 59, No. 1, 1994, pp. 17-22.

[24]   Y. Soini, S. C. Chia, W. P. Bennett, J. D. Groopman, J. S. Wang, V. M. DeBenedetti, et al., “An Aflatoxin-Associated Mutational Hotspot at Codon 249 in the p53 Tumor Suppressor Gene occurs in Hepatocellular Carcinomas from Mexico,” Carcinogenesis, Vol. 17, No. 5, 1996, pp. 1007-1012. doi:10.1093/carcin/17.5.1007

[25]   J. L. Rodríguez-Díaz, V. Rosas-Camargo, O. Vega-Vega, D. Morales-Espinosa, A. Méndez-Reguera, J. L. Martínez-Tlahuel, et al., “Clinical and Pathological Factors Associated with the Development of Hepatocellular Carcinoma in Patients with Hepatitis Virus Related Cirrhosis: A Long-Term Follow-Up Study,” Clinical Oncology (Royal College of Radiologists), Vol. 19, No. 3, 2007, pp. 197-203. doi:10.1016/j.clon.2006.12.005

[26]   J. M. Mejía-Arangure, O. Beutelspacher-Vázquez, S. Juárez-Ocana, J. Vázquez-Langle, M. C. Martínez-García and A. Fajardo-Gutiérrez, “Incidence Trends of Hepatic Tumors in Childhood. Tendencia de la Incidencia de Los Tumores Hepáticos en la Infancia,” Salud Pública de México, Vol. 44, No. 2, 2002, pp. 100-107. doi:10.1590/S0036-36342002000200003

[27]   R. Mondragón-Sánchez, F. J. Ochoa-Carrillo, J. M. Ruiz-Molina, R. Herrera-Goepfer, L. F. Onate-Ocana and V. Aiello-Crocifoglio, “Hepatocellular Carcinoma. Experience at the Instituto Nacional de Cancerología,” Revista de Gastroenterología de México, Vol. 62, No. 1, 1997, pp. 34-40 [Spanish].

[28]   J. Arista-Nasr, L. Gutiérrez-Villalobos, J. Nuncio, H. Maldonaldo and L. Bornstein-Quevedo, “Fibrolamellar Hepatocellular Carcinoma in Mexican Patients,” Pathology and Oncology Research, Vol. 8, No. 2, 2002, pp. 133-137. doi:10.1007/BF03033723

[29]   E. Hernández-Castillo, R. Mondragón-Sánchez, A. L. Garduno-López, E. Gómez-Gómez, J. M. Ruiz-Molina, L. F. Onate-Ocana, et al., “Hepatocellular Carcinoma in the Youth. A Comparative Analysis with Hepatocellular Carcinoma in Adulthood,” Hepatogastroenterology Vol. 52, No. 63, 2005, pp. 903-907.

[30]   L. E. Moreno-Luna, O. Arrieta, J. García-Leiva, B. Martínez, A. Torre, M. Uribe and E. León-Rodríguez, “Clinical and Pathological Factors Associated with Survival in Young Patients with Fibrolamellar Hepatocarcinoma,” BMC Cancer, Vol. 5, 2005, p. 142. doi:10.1186/1471-2407-5-142

[31]   J. Meza-Junco, A. Montano-Lozab and M Candelaria, “Treatment Modalities in Patients with Hepatocellular Carcinoma: A Retrospective Series in a Single Institution in Mexico,” “Modalidades de Tratamiento Para Pacientes con Carcinoma Hepatocelular: Una Serie Retrospectiva de Una Sola Institución en México,” Journal of Gastroenterology and Hepatology, Vol. 27, No. 1, 2004, pp. 11-17. doi:10.1157/13056030

[32]   R. Mondragón-Sánchez, A. L. Garduno-López, E. Hernández-Castillo, E. Gómez-Gómez and J. M. Ruiz-Molina, “Hepatocellular Carcinoma and Hepatitis C in Mexico,” Hepatogastroenterology, Vol. 52, No. 64, 2005, pp. 1159-1162.

[33]   L. Ladrón de Guevara, P. Rojas-Macuil, X. Sánchez-Chávez, A. Rossano-García, M. T. Gorraez-de-la-Mora, G. Cervantes-Sánchez, et al., “Hepatocellular Carcinoma: Epidemiological Profile from a Cohort of Federal Employees in Mexico,” Annals of Hepatology, Vol. 8, No. 3, 2009, pp. 212-219.

[34]   J. L. Cervera, “Fibrolamellar Carcinoma in a Young Patient,” Ann Hepatol, Vol 1, No. 4, 2002, pp. 197-198.

[35]   A. Dardón, R. Corona and N. Méndez-Sánchez, “Hepatocellular Carcinoma Not Associated with Virus B and C and Alcohol,” Annals of Hepatology, Vol. 2, No. 1, 2003, p. 46.

[36]   J. L. Valderrama-Landaeta, A. Güemez Meza, O. Albores Zúniga and J. M. R. Molina, “Fibrolamellar Hepatocellular Carcinoma: A Case Presentation and Literature Review,” “Hepatocarcinoma Fibrolamelar: A Propósito de un Caso y Revisión de la Literatura,” Revista Médica de la Extensión Portuguesa, Vol. 1, No. 1, 2007, pp. 24-28. http://www.saber.ula.ve/bitstream/123456789/24783/1/ articulo4.pdf

[37]   J. Meza-Junco, A. J. Montano-Loza, B. Martínez-Benítez and E. Kimura-Hayama, “Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases: Two Case Reports and Literature Review,” Annals of Hepatology, Vol. 6, No. 2, 2007, pp. 122-126.

[38]   C. Bosetti, T. Rodriguez, L. Chatenoud, P. Bertuccio, F. Levi, E. Negri, et al., “Trends in Cancer Mortality in Mexico, 1981-2007,” European Journal of Cancer Prevention, Vol. 20, No. 5, 2011, pp. 355-363. doi:10.1097/CEJ.0b013e32834653c9

[39]   A. Panduro, M. Maldonado-Gonzalez, N. A. Fierro and S. Roman, “Distribution of Hepatitis B Virus Genotypes F and H in Mexico and Central America,” Antiviral Therapy, 2013 (in Press).

[40]   E. Chiquete and A. Panduro, “Low Prevalence of Anti-Hepatitis C Virus Antibodies in Mexico: A Systematic Review,” Intervirology, Vol. 50, No. 1, 2007, pp. 1-8. doi:10.1159/000096306

[41]   A. Panduro, G. Escobedo-Meléndez, N. A. Fierro, B. Ruiz-Madrigal, E. A. Zepeda-Carrillo and S. Román, “Epidemiology of Viral Hepatitis in Mexico. Epidemiología de las Hepatitis Virales en México,” Salud Pública de México, Vol. 53, Supl. 1, 2011, pp. S37-S45.

[42]   F. H. Pujol, M. C. Navas, P. Hainaut and I. Chemin, “Worldwide Genetic Diversity of HBV Genotypes and Risk of Hepatocellular Carcinoma,” Cancer Letters, Vol. 286, No. 1, 2009, pp. 80-88. doi:10.1016/j.canlet.2009.07.013

[43]   S. E. Livingston, J. P. Simonetti, B. J. McMahon, L. R. Bulkow, K. J. Hurlburt, C. E. Homan, et al., “Hepatitis B Virus Genotypes in Alaska Native People with Hepatocellular Carcinoma: Preponderance of Genotype F,” The Journal of Infectious Diseases, Vol. 195, No. 1, 2007, pp. 5-11. doi:10.1086/509894

[44]   J. M. Sánchez-Tapias, J. Costa, A. Mas, M. Bruguera and J. Rodés, “Influence of Hepatitis B Virus Genotype on the Long-Term Outcome of Chronic Hepatitis B in Western Patients,” Gastroenterology, Vol. 123, No. 6, 2002, pp. 1848-1856. doi:10.1053/gast.2002.37041

[45]   F. Pujol, S. Roman, A. Panduro, M. C. Navas and E. Lampe, “Hepatocellular Carcinoma in Latin America,” In: I. Chemin, Ed., Hepatocellular Carcinoma: A Global Challenge, 1st Edition, Nova Science Publishers Inc., New York, 2011, pp. 55-68.

[46]   L. V. Sanchez, M. Maldonado, B. E. Bastidas-Ramirez, H. Norder and A. Panduro, “Genotypes and S-Gene Variability of Mexican Hepatitis B Virus Strains,” Journal of Medical Virology, Vol. 68, No. 1, 2002, pp. 24-32. doi:10.1002/jmv.10166

[47]   L. V. Sánchez, Y. Tanaka, M. Maldonado, M. Mizokami and A. Panduro, “Difference of Hepatitis B Virus Genotype Distribution in Two Groups of Mexican Patients with Different Risk Factors. High Prevalence of Genotype H and G,” Intervirology, Vol. 50, No. 1, 2007, pp. 9-15. doi:10.1159/000096307

[48]   N. A. Fierro, S. Roman, M. Realpe, Z. Hernandez-Nazara, E. A. Zepeda-Carrillo and A. Panduro, “Multiple Cytokine Expression Profiles Reveal Immune-Based Differences in Occult Hepatitis B Genotype H-Infected Mexican Nahua Patients,” Memórias do Instituto Oswaldo Cruz, Vol. 106, No. 8, 2011, pp. 1007-1013.

[49]   F. B. Hollinger and G. Sood, “Occult Hepatitis B Virus Infection: A Covert Operation,” Journal of Viral Hepatitis, Vol. 17, No. 1, 2010, pp. 1-15. doi:10.1111/j.1365-2893.2009.01245.x

[50]   H. L. Chan, M. L. Wong, A. Y. Hui, L. C. Hung, F. K. Chan and J. J. Sung, “Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients,” Journal of Clinical Microbiology, Vol. 41, No. 3, 2003, pp. 1277-1279. doi:10.1128/JCM.41.3.1277-1279.2003

[51]   Z. H. Hernandez-Nazara, B. Ruiz-Madrigal, E. Martinez-Lopez, S. Roman and A. Panduro, “Association of the E2 Allele of ApoE Gene to Hypertriglyceridemia and to Early-Onset of Alcoholic Cirrhosis,” Alcoholism: Clinical and Experimental Research, Vol. 32, No. 3, 2008, pp. 1-8. doi:10.1111/j.15300277.2007.00607.x

[52]   B. E. Bastidas-Ramirez, P. Nuno-Gonzalez, C. Vivas Arceo, L. V. Sanchez-Orozco and A. Panduro, “Albumin mRNA in Peripheral White Blood Cells of Cirrhotic Patients with a Superimposed Alcoholic Hepatitis Is Associated to Fatal Outcome,” Hepatology Research, Vol. 24, No. 3, 2002, pp. 265-274. doi:10.1016/S1386-6346(02)00109-2

[53]   S. C. Chuang, C. La Vecchia and P. Boffetta, “Liver Cancer: Descriptive Epidemiology and Risk Factors Other than HBV and HCV Infection,” Cancer Letters, Vol. 286, No. 1, 2009, pp. 9-14. doi:10.1016/j.canlet.2008.10.040

[54]   T. J. Key, A. Schatzkin, W. C. Willett, N. E. Allen, E. A. Spencer and R. C. Travis, “Diet, Nutrition and the Prevention of Cancer,” Public Health Nutrition, Vol. 7, No. 1A, 2004, pp. 187-200. doi:10.1079/PHN2003588

[55]   T. W. Kensler, B. D. Roebuck, G. N. Wogan and J. D. Groopman, “Aflatoxin: A 50-Year Odyssey of Mechanistic and Translational Toxicology,” Toxicological Sciences, Vol. 120, Suppl. 1, 2011, pp. S28-S48. doi:10.1093/toxsci/kfq283

[56]   Y. Liu and F. Wu, “Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment,” Environmental Health Perspectives, Vol. 118, No. 6, 2010, pp. 818-824. doi:10.1289/ehp.0901388

[57]   C. Wacher, “Nixtamalization, A Mesoamerican Technology to Process Maize at Small Scale with Great Potential for Improving the Nutritional Quality of Maize Based Foods,” 2nd International Workshop. Food-Based Approaches for a Healthy Nutrition, Ouagadougou, 23 November 2003, pp. 1-10. http://www.univ-ouaga.bf/conferences/fn2ouaa2003/abstracts/0715_FP_O4_Mexico_Wacher.pdf

[58]   G. L. Anguiano-Ruvalcaba, A. V. Vargas-Cortina and D. G.-D. Pena, “Inactivation of Aflatoxin B1 and Aflatoxicol through Traditional ‘Nixtamalización’ of Corn and Their Regeneration by Acidification of Corn Dough,” Salud Pública de México, Vol. 47, No. 5, 2005, pp. 369-375. doi:10.1590/S0036-36342005000500007

[59]   M. Malvezzi, C. Bosetti, L. Chatenoud, T. Rodriguez, F. Levi, E. Negri, et al., “Trends in Cancer Mortality in Mexico, 1970-1999,” Annals of Oncology, Vol. 15, No. 11, 2004, pp. 1712-1718. doi:10.1093/annonc/mdh424

[60]   N. Méndez-Sánchez, A. R. Villa, N. C. Chávez-Tapia, G. Ponciano-Rodríguez, P. Almeda-Valdés, D. González, et al., “Trends in Liver Disease Prevalence in Mexico from 2005 to 2050 through Mortality Data,” Annals of Hepatology, Vol. 4, No. 1, 2005, pp. 52-55.

[61]   N. Méndez-Sánchez, A. R. Villa, G. Vázquez-Elizondo, G. Ponciano-Rodríguez and M. Uribe, “Mortality Trends for Liver Cancer in Mexico from 2000 to 2006,” Annals of Hepatology, Vol. 7, No. 3, 2008, pp. 226-229.

[62]   A. P. Venook, C. Papandreou, J Furuse and L. Ladrón de Guevara, “The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective,” The Oncologist, Vol. 15, Suppl. 4, 2010, pp. 5-13. doi:10.1634/theoncologist.2010-S4-05

[63]   E. Fassio, S Diaz, C. Santa, M. E. Reig, Y. Martínez Artola, A. Alves de Mattos, et al., Multicenter Group for Study of Hepatocarcinoma in Latin America, “Etiology of Hepatocellular Carcinoma in Latin America: A Prospective, Multicenter, International Study,” Annals of Hepatology, Vol. 9, No. 1, 2010, pp. 63-69.

 
 
Top